TARDBP and amyotrophic lateral sclerosis: Emerging in vivo studies have investigated treatment strategies using either small molecule inhibitors or antibodies targeting S409/410 phosphorylation sites within the C-terminus of TDP-43 in various ALS-related mouse models.